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ttp://dx.doi.org/10.1016/j.ajpath.2012.07.036Tumor functional and molecular imaging has signiﬁcantly contributed to cancer preclinical research and
clinical applications. Among typical imaging modalities, ultrasonic and optical techniques are two
commonly used methods; both share several common features such as cost efﬁciency, absence of
ionizing radiation, relatively inexpensive contrast agents, and comparable maximum-imaging depth.
Ultrasonic and optical techniques are also complementary in imaging resolution, molecular sensitivity,
and imaging space (vascular and extravascular). The marriage between ultrasonic and optical techniques
takes advantages of both techniques. This review introduces tumor functional and molecular imaging
using microbubble-based ultrasound and ultrasound-mediated optical imaging techniques. (Am J Pathol
2013, 182: 305e311; http://dx.doi.org/10.1016/j.ajpath.2012.07.036)Supported in part by NIH/National Institute of Biomedical Imaging and
Bioengineering grant 7R15EB012312-02 (B.Y.), the Cancer Prevention and
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This article is part of a review series on imaging in small animal models.
Disclosures: J.R. has equity and employment with Targeson. Targeson also
has commercial products related to the science that are discussed in this review.Tumor in vivo and noninvasive imaging has signiﬁcantly
contributed to cancer preclinical research and clinical
applications.1 With the introduction of contrast agents,
imaging techniques have been extended from conventional
structural (anatomical) imaging to functional (physiological)
and molecular (biochemical) imaging.1,2 Although structural
information is important for tumor localization and assess-
ment of size, shape, and boundary, functional/molecular
imaging can evaluate tumor physiological status such as
abnormal microenvironments, hypoxia and angiogenesis,
metabolism, malignancy, and metastasis, which is critical,
not only for clinical applications, but also for understanding
cancer’s underlying mechanisms (via investigating gene
expression, signaling pathways, receptors, apoptosis, etc.).1,2
Currently, several techniques are widely used for preclin-
ical and clinical cancer imaging, such as computed tomo-
graphy (CT), single-photon emission computed tomography
(SPECT), positron emission tomography (PET), magnetic
resonance imaging (MRI), ultrasound, and optical techni-
ques.1,2 These imaging modalities have been very successful
in tumor imaging. Unfortunately, none of them is perfect.
Although imaging depth is not a problem, clinically used CT
and MRI have a spatial resolution ofw1 mm, and clinicallystigative Pathology.
.used PET and SPECT provide an even worse spatial resolu-
tion (>3 mm). Micro-CT (w20 to 50 mm) and micro-MRI
(w50 mm) can provide high-resolution images by reducing
imaging volume and increasing exposure dosage. However,
CT or micro-CT may not be an excellent tool to differentiate
different soft tissues. MRI and micro-MRI have been used
for tissue molecular imaging. One of the limitations is that
the sensitivity to imaging contrast agents is low compared
with PET, SPECT, and optical techniques. In addition, due to
the complexity of cancer, no single imaging modality is
sufﬁcient to obtain all of the desired information.3 Contrast-
enhanced techniques and multimodality imaging are exp-
ected to offer new and synergistic advantages over one
modality on its own.3e5
Ultrasound and optical techniques share many common
features.5e7 For example, both are cost efﬁcient and safe.
Yuan and RychakAlso, their maximum imaging depths are comparable and
can reach down to tens of millimeters with fast imaging
speed,8 which is excellent for studying small animals and
some human organs, such as the breast and prostate. The
contrast agents of both techniques have been well developed
and are generally inexpensive (for example, microbubbles
for ultrasound and dyes or nanoparticles for optical imaging).
Besides the common features, the two imaging techniques
are also complementary.6 Although optical techniques suffer
from low spatial resolution (2 to 5 mm for diffuse optical
tomography) due to light scattering in deep tissues (20 to
50mm), ultrasound ismuch less scattered by tissue and features
with relatively higher resolutions, tens to hundreds of microns
depending on the frequency, at similar imaging depth.
Conversely, ultrasound alone is insensitive to tissue functional
and molecular information, and requires the use of exogenous
contrast agents.5Microbubbles are themost efﬁcacious contrast
agent for ultrasound imaging. Because of the relatively large
size (a few microns in diameter), microbubbles are usually
limited to inside the tumor’s vascular system for detecting
blood perfusion, velocity, and intravascular molecular
targets.5,8 By contrast, optical techniques are not only sensitive
to tissue functional/molecular events and capable of simulta-
neous imaging of multiple molecular events via spectroscopic
techniques, but also can image both vascular and extravascular
molecular targets.9 Accordingly, microbubble-based ultra-
sound and ultrasound-mediated optical imaging techniques
have been intensively developed during the past years for tumor
imaging.5,6,8,10 As expected, the marriage between ultrasound
and optical techniques takes advantages of both techniques, and
signiﬁcant progress has been achieved recently.6,10
In this review, microbubble-enhanced ultrasound tumor
imaging will be introduced ﬁrst. It is followed by ultrasound-
mediated optical imaging techniques that include: i)
ultrasound-guided diffuse optical tomography (UG-DOT)10;
ii) photoacoustic tomography/microscopy (PAT/PAM)6;
and iii) ultrasound-modulated optical tomography/micro-
scopy (UMOT/UMOM).11Microbubble-Based Ultrasound Tumor Imaging
The mechanism of the contrast effect in ultrasound imaging is
a mismatch in acoustic impedance, and contrast agents for-
ultrasound are substances that exhibit altered acoustic imped-
ance relative to the surrounding biological milieus. The most
commonlyusedultrasound contrast agents are gas-encapsulated
microparticles, also known as microbubbles. Microbubbles
generally exhibit a diameter in the range of 1 to 5 mm.12 The
microscopic dimension renders these agents purely intravas-
cular,13,14 as they are too large to pass through the vascular
endothelium into the extravascular space. This limits the range
of potential molecular targets to those expressed on the luminal
vascular endothelium and associated cells.
Contrast agents were initially developed for blood pool
imaging and used as tracers to detect blood ﬂow. The use306of these agents presents dynamical information, enabling
visualization of ﬂow patterns and velocity. Alternatively, the
contrast agents need to bind to their molecular targets for
ultrasound molecular imaging. Efﬁcacious use of ultrasound
molecular imaging requires: i) the ability to image retained
contrast with high sensitivity; ii) clearance of any unbound
contrast from the imaged area; and iii) ﬁrm retention of the
contrast agent by the molecular target.
Most ultrasound scanners currently implemented in the
ﬁeld have highly sensitive contrast imaging capabilities, and
detection sensitivity is not a signiﬁcant hurdle in most tissues.
In the context of agent clearance, intravascular conﬁnement
offers a compelling beneﬁt: the clearance time for nonetarget-
bound microbubbles is on the order of minutes,5e10 which is
signiﬁcantly faster than imaging techniques using single
molecule tracers that diffuse throughout the body and may
take hours to days to clear.15,16 This enables ultrasound
molecular imaging experiments to be conducted quite rapidly,
generally<15 minutes. Unbound microbubbles clear through
the reticuloendothelial system, primarily in the liver, spleen,
and lungs.17,18 Target-bound microbubbles generally remain
echogenic for up to 30 minutes, providing an ample window
for full examination. The application of high power (within
the diagnostically safe range) can rapidly (approximately
seconds) destroy microbubbles resident within the beam.
This provides a very useful means for resetting the imaging
baseline following an experiment, after which subsequent
agents can be administered.15,16 In this manner, subjects can
be sequentially interrogated with contrast agents targeted to
multiple targets in the same imaging session, which offers
a unique convenience in the context of preclinical research.
Selection of relevant imaging targets and ligands is
important to any molecular imaging technique, although this
issue becomes critical for ultrasound molecular imaging. In
addition to the obligate intravascular nature of the micro-
bubble agent discussed above, the size of these agents render
them susceptible to inertial forces generated by blood
ﬂow.19,20 A microbubble bound to its endothelial target is
exposed to a shear force imposed by blood ﬂow that acts to
dislodge the microbubble from its target. Thus, the utilization
of targeting ligands that exhibit very high afﬁnity is useful.
Early work used monoclonal antibodies as targeting
ligands. This provided the advantage of very high afﬁnity
although the species selectivity of these molecules was
a signiﬁcant limitation. Several strategies for engineering
a translatable ultrasound molecular imaging ligand have
been reported in the context of targeting vascular endothelial
growth factor receptor-2 (VEGFR-2) as a marker of angio-
genesis, including using phage display to identify peptide
sequences that identify distinct epitopes of the VEGFR-2
molecule21 and using a single-chain construct based on
human vascular endothelial growth factor (VEGF).15
In addition to withstanding the dislodging force of blood
ﬂow, a circulating microbubble must also be able to rapidly
bind to its molecular target. The use of targeting ligands pos-
sessing very rapid bond formation rates enabled improvementajp.amjpathol.org - The American Journal of Pathology
Tumor Ultrasound and Optical Imagingof microbubble targeting under conditions of high blood ﬂow
in vivo and in vitro.19,22 Dual targeting, using a ligand with
a fast on-rate and a second ligand with a slower on-rate but
high bond stability, results in highly efﬁcient microbubble
attachment and the ability to withstand detachment.23 Other
strategies for improving microbubble adhesion include
modulation of the microbubble shape19 and the use of exter-
nally applied acoustic radiation force.24,25
Figure 1 shows an example of molecular imaging of
VEGFR-2 in an angiogenic tumor in a mouse. Figure 1A is
a B-mode image showing a subcutaneous tumor (outlined in
white). The image sequence in Figure 1B shows the time
course of VEGFR-2etargeted agent uptake in the tumor, with
microbubble contrast depicted in shades of orange. The ﬁrst
image shows essentially no contrast signal before the contrast
is administered (the pre-contrast baseline). The next image,
taken 2 seconds after agent injection, shows that the micro-
bubbles perfuse the entire tumor mass. The ﬁnal panel, taken
at 6 minutes after circulating microbubbles have cleared,
shows selective agent uptake at the rim, but not within
the center, of the tumor. Similar images are presented in
Figure 1C for a control microbubble (bearing an inactivated
targeting ligand): the microbubbles perfuse the entire tumor,
but are not taken up. This behavior is represented graphically
in Figure 1D, showing a persistent contrast signal for the
VEGFR-2etargeted, but not control, microbubbles.
Tumor Imaging Based on Ultrasound-Mediated
Optical Imaging
As mentioned above, microbubble-based applications have
been limited to the tumor vascular system due to the relatively
large size of microbubble. Ultrasound-mediated optical
imaging techniques are free from this limitation. Depending on
whether and how the ultrasound waves interact with light
diffusion in tissue, three types of hybrid imagingmethods have
been demonstrated. In the ﬁrst method, no physical interactionFigure 1 Example of molecular imaging of VEGFR-2 in an angiogenic tumor. A
VEGFR-2etargeted agent uptake in the tumor. C: Similar images acquired from non
and C. Images were produced by J.R., assisted by Chris Anderson (Targeson, Inc
The American Journal of Pathology - ajp.amjpathol.orgoccurs between ultrasound waves and light.26 Ultrasound is
used only to guide optical imaging. This technique is known as
UG-DOT. The second method is based on the generation of
one signal from the other. Generation of ultrasonic signal using
light is called photoacoustic (PA) effect.6 Conversely, gener-
ation of light by ultrasound is known as sonoluminescence,
which has been demonstrated for tissue imaging.27 However,
further development is difﬁcult due to its weak signal and,
therefore, will not be reviewed here. The third method is based
on ultrasound-modulated light,11 which is referred to as
UMOT/UMOM and will be brieﬂy discussed below.
Ultrasound-Guided Diffuse Optical Tomography
Optical microscopy can provide high (submicron) spatial
resolution by detecting nonscattered light in tissue, but this
methodmakes it extremely difﬁcult to imagedeeper than 1mm
in most biological tissues due to high light scattering.28 By
contrast, signiﬁcantly scattered light (usually called diffuse
light) can travel much deeper into tissue (tens of millimeters
using red or near infrared light). By taking advantage of
this fact, near-infrared spectroscopy has been developed to
measure the change of the hemoglobin concentration and its
oxygenation in deep tissues. However, near-infrared spec-
troscopy cannot provide an image to show the spatial distri-
bution of themeasured signal. To achieve deep-tissue imaging,
diffuse optical tomography (DOT) has been developed, which
has been very successful in imaging oxyhemoglobin (HbO2),
deoxyhemoglobin (HbR), and total hemoglobin and oxy-
genation in breast and prostate tumors.10,29 By injecting or
attaching ﬂuorescent molecules to tumor cells, ﬂuorescence
DOT [(F)DOT] has been introduced to imaging hemody-
namics and molecular events in deeply seated tumors.7
Due to the adoption of diffuse light, the spatial resolution
of (F)DOT is limited to a few millimeters. Therefore, the
capability of tumor localization is poor, which further leads
to the degradation of the accuracy of the reconstructed: A B-mode ultrasound image of subcutaneous tumor. B: The time course of
targeting microbubbles (MB) as control. D: Dynamic ultrasonic signals of B
., San Diego, CA).
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deploying optical sensors and an ultrasound transducer on
a hand-held probe (a commercial US transducer located in
the center, and near-infrared light source and detector ﬁbers
distributed at the periphery), the tumor can be imaged by
two modalities: ultrasound and (F)DOT.10,29,30 Generally,
the ultrasound system is used to localize the tumor and ﬁnd
its structural (or anatomical) parameters, such as the depth
and size. On the basis of this structural information, the (F)
DOT technique is used to image tumor functional/molecular
information, such as oxy-, deoxy-, and total hemoglobin or
tumor-related molecules.10,29,30
For example, images acquired from a UG-DOT system are
given in Figure 2.10 Figure 2A displays the ultrasonic and
optical images of a benign (ﬁbroadenoma) breast tumor. The
ultrasound image shows the cross section of the tumor (x-z
plane), depicting a 7-mm lesion located between 15 and
20 mm deep from the skin. The tumor structural information
was used as prior information to reconstruct the optical images.
Each slice shows the optical image on the x-y plane at
a different depth. The step-size in the depth direction (z) was 5
mm. The color of the optical images represents the calculated
total hemoglobin concentration. Slice No. 4 (representing
a depth of 18 mm) clearly showed the existence of a lesion
with a maximum and an average of total hemoglobin of 35.3
and 24.7 mmol/L, respectively. Core biopsy indicated
a ﬁbroadenoma. Similarly, Figure 2B shows the images of
a malignant tumor (invasive carcinoma). The ultrasound
image indicated the lesion had a size around 9 mm and was
located at a depth ofw13mm. The optical image of slice No. 3
(representing a depth of 13 mm) clearly showed the existence
of the lesion with a maximum and an average of total hemo-
globin of 112.3 and 75.8 mmol/L, respectively. The coreFigure 2 A: Ultrasonic (top panel) and optical (bottom panel) images of a b
Conﬁguration is similar to that in A. C: Serial PA images showing the development
a glioblastoma in a mouse brain based on a contrast agent of IRDye800 conjugate
based on spatial resolution and imaging depth. HFUS, high-frequency ultraso
permission of the Radiology Society of North America (copyright 2010) (A and B),
and Li et al39 with permission of the IEEE (copyright 2008) (D).
308biopsy revealed an invasive carcinoma. It is understandable
that the invasive carcinoma had higher total hemoglobin than
the benign ﬁbroadenoma because invasive tumors grow
quickly and need more blood to provide nutrients and oxygen.
However, hemoglobin concentration cannot be seen from pure
ultrasound images. Therefore, UG-DOT is considered
a potential tool for assisting with cancer diagnoses based on
functional information.
Besides imaging breast cancer, UG-DOT has also been used
to investigate prostate cancer, based on a similar principle.29 A
transrectal probe combining an ultrasound transducer and
optical ﬁbers has been designed. Promising results have been
reported recently in dogs for assisting prostate cancer detection
and diagnosis.29 When exogeneous contrast agents are adop-
ted, such as indocyanine green, tumor image contrast can be
further improved and tumor hemodynamics can be investigated
based on the measured dynamics of the contrast agents.7,30
When adopting a near-infrared dye of cyanine 7 conjugated
with VEGF, the overexpressed VEGFR-2 in angiogenic blood
vessels of a mouse tumor has been imaged based on a similar
principle.31 Currently, many types of ﬂuorescence contrast
agents have been developed, from small molecules (such as
organic dyes) to ﬂuorescence nanoparticles (such as quantum
dots), polymers, andmicrospheres. They are usually larger than
those atom-based contrast agents, such as gadolinium in MRI.Photoacoustic Tomography/Microscopy
Whereas UG-DOT can provide both optical functional/
molecular and ultrasonic structural information of a deeply
seated tumor,26,32,33 the optical spatial resolution is still
limited by diffuse light, which is usually at a level ofenign human breast tumor. B: An invasive carcinoma human breast cancer.
of tumor angiogenic blood vessels in a rat. D: A PA image showing avb3 in
d with cyclic peptide cyclo. E: A summary of the discussed imaging methods
und; LFUS, low-frequency ultrasound. Reproduced from Zhu et al10 with
Siphanto et al44 with permission of the Optical Society (copyright 2005) (C),
ajp.amjpathol.org - The American Journal of Pathology
Tumor Ultrasound and Optical Imagingmillimeters and unable to visualize the details of a deep
tumor (such as microcirculation and microenvironments).
The development of PA imaging techniques has overcome
this limitation.6
The fundamentals of PA tomography (PAT)/PA micros-
copy (PAM) have been intensively described in the litera-
ture.34 Brieﬂy, when an optical absorber (such as hemoglobin
and melanin) is illuminated with a very short (approximately
nanoseconds) laser pulse, the pulse energy is partially absor-
bed and converted into heat. A rapid and local temperature rise
occurs due to the light-induced heating. Thus, a local pressure
increase occurs due to thermoelastic expansion, which is
called initial PA pressure. This initial PA pressure is propor-
tional to the local tissue optical absorption coefﬁcient. After
the light illumination, the local initial PA pressure cannot
be further maintained and, therefore, propagates outside the
tissue as ultrasonic waves called PA signals. By detecting
these PA signals using ultrasound transducers placed outside
the tissue, the local initial pressure and, therefore, the local
tissue-optical absorption can be quantiﬁed. Therefore, PA
techniques provide images with optical absorption contrast
that reﬂect tissue’s physiological and molecular information
with ultrasonic resolution. Depending on the central fre-
quency and bandwidth of the used ultrasound transducers, the
spatial resolution and imaging depth are scalable.6 For
example, when the imaging depth is 38 mm, the lateral and
axial resolutions can reach 560 and 144 mm, respectively, by
using a 5-MHz ultrasound transducer.35 The lateral and axial
resolutions can be improved to 45 and 15 mm, respectively, by
using a 50-MHz ultrasound transducer, but at the expense of
the imaging depth, which is reduced down to 3 mm.36
Depending on the wavelength of the adopted laser, the
major intrinsic absorbers in tissue include hemoglobin,
melanin, water, lipids, and nucleic acid.37 Therefore, PA
techniques can be used to image these components in a three-
dimensional mode in tissue. For example, HbO2 and HbR are
the major absorbers in blood. To be able to quantify the
concentrations of HbO2 and HbR, at least two wavelengths
should be used where the HbO2 andHbR absorb differently at
the two wavelengths. After the quantiﬁcation of the
concentrations of HbO2 and HbR, the total hemoglobin
concentration and oxygen saturation of hemoglobin can be
calculated.38
Angiogenesis (the growth of new blood vessels for oxygen
and nutrition supply), one of the hallmarks of a solid tumor,
has been accepted as an important indicator for tumor detec-
tion and an important target for treatment.3 PA techniques
have successfully shown the great capability of imaging tumor
angiogenesis and hypoxia in animals and humans with high
spatial resolution and large imaging depth in various types
of tumors, such as tumors of the breast, prostate, brain, skin,
pancreas, ovary, and other organs.34,39e43 The temporal
development of angiogenesis in an implemented pancreatic
tumor in a rat, for example, has been three-dimensionally
imaged using PAT (Figure 2C)44 Speciﬁcally, 6  106
tumor cells (CA20948) were subcutaneously injected inThe American Journal of Pathology - ajp.amjpathol.orgthe right hind limb of a male Lewis rat. A volume of 1.5 
1.5  0.5 cm3 around the inoculation site was imaged during
days 3, 7, 8, and 10 after day 1 of inoculation. No blood
vessels were observed in day 3 from the PA images. Indi-
vidual blood vessels were formed and grown in the tumor
between day 3 and day 7. After day 7, the vessels became
deeper. This study demonstrates the capability of PA tech-
niques to monitor the development of tumor angiogenesis
based on the elevated hemoglobin concentration with optical
contrast and ultrasonic spatial resolutions.44
Besides the endogenous optical absorbers mentioned
above, exogenous contrast agents for PA imaging have
attracted much attention recently because these contrast
agents provide great opportunities to extend PA techniques
to image molecules and/or chemicals in tumors.34 Currently,
several types of the contrast agents have been investigated,
including organic dyes (such as indocyanine green, IRDye-
800, and methylene blue), nanoparticles (such as gold
nanocages, nanoshells, nanorods, and single-walled carbon
nanotubes), reporter genes, ﬂuorescence proteins, and
micro-/nanobubbles.45 Because PA techniques are based on
light absorption, an appropriate absorbing unit should be
included in the designed PA imaging contrast agents.
A targeting unit (such as a ligand or peptide) is needed for
the contrast agents to be uniquely attached to the molecules
to be imaged. For example, integrin avb3 has been found
overexpressed in the endothelial cells of tumor angiogenic
blood vessels.3 Imaging of integrin avb3 provides a unique
opportunity to understand the tumor angiogenesis mecha-
nism at the molecular level.3,39 IRDye800-NHS (an indoc-
yanine green derivative as a light absorber) was conjugated
with cyclic peptide cyclo (Lys-Arg-Gly-Asp-Phe) (avb3
targeting unit) and used for imaging avb3 in glioblastoma at
a wavelength of 800 nm (Figure 2D).39 Another example is
to image human epidermal growth factor receptor 2 (HER2)
and epidermal growth factor receptor (EGFR) in squamous
cell carcinoma by using gold nanorods at 785 or 1000 nm.40
The success of PA tumor molecular imaging has signiﬁ-
cantly extended the power of this technique into the ﬁelds of
basic scientiﬁc research about tumors and also preclinical
and clinical applications.Ultrasound-Modulated Optical Tomography/
Microscopy
Ultrasound-modulated optical tomography/microscopy
(UMOT/UMOM) uses a focused ultrasound beam to
modulate (or tag) diffuse photons in focal volume.11 When
the acoustic wave oscillates the tissue, scattering particles,
the optical phase of the scattered photons can be modulated
via the modulations of optical path lengths and/or tissue
refractive indexes. Due to the coherence of light, optical
interference occurs between modulated and unmodulated
photons. Therefore, intensity-modulated speckles can be
observed at the tissue surface. By quantifying the oscillation309
Yuan and Rychakof these speckles, the modulated photons can be extracted
and quantiﬁed. Because modulated photons must pass
through the ultrasound focal volume, the spatial resolution
of UMOT/UMOM depends on the ultrasound focal size
(lateral) and pulse width (axial). However, the modulated
photons are also related to tissue optical absorption coefﬁ-
cients. When less modulated photons are observed, it means
higher optical absorption in the ultrasound focal volume.
Thus, the image provides a negative contrast of optical
absorption coefﬁcients with ultrasound resolution.11 A low
ultrasound frequency (<15 MHz) is usually adopted in
UMOT for achieving a large imaging depth, and a high
ultrasound frequency (>30 MHz) should be selected for
high-resolution imaging in shallow tissues (Figure 2E).
Currently, UMOT/UMOM has been intensively studied in
tissue-like phantoms and ex vivo tissue samples (such as
lymph nodes).46 However, due to its low signal-to-noise
ratio, signiﬁcant studies have to be done to improve the
signal levels. New methods are under investigation to
improve signal-to-noise ratio, such as spectral hole-burning
techniques47 and slowing light techniques.48 When tissue
is labeled with ﬂuorophores, the ﬂuorescence emission
intensity can be also modulated by a focused ultrasound
wave. By detecting the modulated ﬂuorescence signal, ﬂu-
orophore concentration can be quantiﬁed with ultrasound
resolution in deep tissues.49,50 However, due to the inco-
herent properties of ﬂuorescence, the modulation mecha-
nisms are still not clearly understood, and the modulation
signals are considerably weak. Further improvements are
under investigation.50
Technical Comparison Among the Major Optical
and Ultrasound-Related Imaging Techniques
Figure 2E summarizes the imaging techniques discussed
above based on the spatial resolution and imaging depth.
The three tilted dashed lines represent the depth-to-
resolution ratios (DRRs) that equal to 10, 100, and 1000,
respectively. (F)DOT and UG-DOT are roughly located on
the line of DRR Z 10. Low-frequency ultrasound, high-
frequency ultrasound, PAT, PAM, UMOT, and UMOM
have improved the DRR 100. The area at the left bottom
corner of Figure 2E is for optical microscopy. By combining
with imaging contrast agents, such as microbubbles, or
optical imaging methods, functional/molecular information
of tissues can be imaged with different DRRs.
Conclusion
The use of microbubble contrast agents has extended
ultrasonic techniques from conventional structural imaging
to functional/molecular imaging. However, the micron size
of a microbubble limits the technique to assessment of
diseases with a vascular component. The combination of
ultrasonic and optical techniques has overcome this310limitation by detecting optical contrast (optical absorption
and/or ﬂuorescence) with ultrasonic spatial resolution. UG-
DOT uses ultrasound-acquired tumor structural information
to reconstruct tumor optical functional information, such as
oxy-, deoxy-, and total hemoglobin concentrations, that is
correlated with tumor physiological status and malignancy.
This technique can provide accurate tumor functional/
molecular information, but the spatial resolution (a few
millimeters) is poor and unable to image details in the tumor
(such as tumor angiogenic blood vessels). The advent of
PAT/PAM has overcome this limitation. The small blood
vessels in deep tumors can be clearly visualized, and the
dynamic development of tumor angiogenesis, hypoxia,
and molecular events can be investigated relatively easier
compared to other expensive imaging modalities. Although
UMOT/UMOM is still limited by the signal-to-noise ratio,
the results in tissue phantoms and ex vivo samples indicate
that it is a promising imaging modality. Further deve-
lopment in microbubble-based ultrasound and ultrasound-
mediated optical imaging techniques will signiﬁcantly
contribute to cancer preclinical research and clinical
applications.References
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